218 related articles for article (PubMed ID: 8126248)
21. Erythropoietin and anemia.
Tong EM; Nissenson AR
Semin Nephrol; 2001 Mar; 21(2):190-203. PubMed ID: 11245780
[TBL] [Abstract][Full Text] [Related]
22. [Management of renal anemia in 2013].
Gianella P; Martin PY; Stucker F
Rev Med Suisse; 2013 Feb; 9(375):462-4, 466-7. PubMed ID: 23539813
[TBL] [Abstract][Full Text] [Related]
23. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
Eschbach JW; Varma A; Stivelman JC
Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
[TBL] [Abstract][Full Text] [Related]
24. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
Campos A; Garin EH
Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
[TBL] [Abstract][Full Text] [Related]
25. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
26. Adjunctive therapy in anaemia management.
Hörl WH
Nephrol Dial Transplant; 2002; 17 Suppl 5():56-9. PubMed ID: 12091609
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin and the anemia of chronic diseases.
De Marchi S; Pirisi M; Ferraccioli GF
Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
[TBL] [Abstract][Full Text] [Related]
28. The use of recombinant human erythropoietin [rHuEpo] in man.
Adamson JW; Eschbach JW
Prog Clin Biol Res; 1990; 352():505-17. PubMed ID: 2205875
[No Abstract] [Full Text] [Related]
29. Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses.
Ribeiro S; Garrido P; Fernandes J; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
Biofactors; 2016 May; 42(3):296-306. PubMed ID: 26990350
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin 1997: a brief update.
Gahl GM; Eckardt KU
Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
[No Abstract] [Full Text] [Related]
31. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
32. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy.
Eschbach JW; Adamson JW
Kidney Int Suppl; 1999 Mar; 69():S35-43. PubMed ID: 10084284
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
34. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
35. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy.
Kawamura A; Higuchi M; Imai N; Kawaguchi T; Ogura Y
Biotherapy; 1990; 2(1):77-85. PubMed ID: 2400629
[TBL] [Abstract][Full Text] [Related]
36. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
Lezaic V; Djukanovic L; Pavlovic-Kentera V
Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
[TBL] [Abstract][Full Text] [Related]
38. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
39. Resistance to recombinant human erythropoietin in hemodialysis patients.
Drüeke TB
Am J Nephrol; 1990; 10 Suppl 2():34-9. PubMed ID: 2260616
[TBL] [Abstract][Full Text] [Related]
40. [Renal anemia - an important secondary disease in renal insufficiency].
Mayer C; Achenbach H; Stumvoll M; Fiedler G
Internist (Berl); 2006 Mar; 47(3):233-4, 236-8, 240-1. PubMed ID: 16470356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
